{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T23:58:13Z","timestamp":1792108693558,"version":"4.4.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2021,5,16]],"date-time":"2021-05-16T00:00:00Z","timestamp":1621123200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,5,16]],"date-time":"2021-05-16T00:00:00Z","timestamp":1621123200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CNS Drugs"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1007\/s40263-021-00819-8","type":"journal-article","created":{"date-parts":[[2021,5,16]],"date-time":"2021-05-16T05:02:35Z","timestamp":1621141355000},"page":"609-618","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":150,"title":["Pharmacology of Cenobamate: Mechanism of Action, Pharmacokinetics, Drug\u2013Drug Interactions and Tolerability"],"prefix":"10.1007","volume":"35","author":[{"given":"Roberta","family":"Roberti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"De Caro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luigi Francesco","family":"Iannone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaetano","family":"Zaccara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simona","family":"Lattanzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1279-8123","authenticated-orcid":false,"given":"Emilio","family":"Russo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,5,16]]},"reference":[{"key":"819_CR1","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1159\/000503831","volume":"54","author":"E Beghi","year":"2020","unstructured":"Beghi E. The epidemiology of epilepsy. Neuroepidemiology. 2020;54:185\u201391.","journal-title":"Neuroepidemiology"},{"key":"819_CR2","doi-asserted-by":"publisher","first-page":"e551","DOI":"10.1016\/S2468-2667(20)30190-0","volume":"5","author":"G Deuschl","year":"2020","unstructured":"Deuschl G, Beghi E, Fazekas F, Varga T, Christoforidi KA, Sipido E, et al. The burden of neurological diseases in Europe: an analysis for the Global Burden of Disease Study 2017. Lancet Public Health. 2020;5:e551\u201367.","journal-title":"Lancet Public Health"},{"key":"819_CR3","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1001\/jamaneurol.2017.3949","volume":"75","author":"Z Chen","year":"2018","unstructured":"Chen Z, Brodie MJ, Liew D, Kwan P. Treatment outcomes in patients with newly diagnosed epilepsy treated with established and new antiepileptic drugs a 30-year longitudinal cohort study. JAMA Neurol. 2018;75:279\u201386.","journal-title":"JAMA Neurol"},{"key":"819_CR4","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/epi.12294","volume":"54","author":"JA French","year":"2013","unstructured":"French JA, White HS, Klitgaard H, Holmes GL, Privitera MD, Cole AJ, et al. Development of new treatment approaches for epilepsy: unmet needs and opportunities. Epilepsia. 2013;54:3\u201312.","journal-title":"Epilepsia"},{"key":"819_CR5","doi-asserted-by":"publisher","first-page":"e2311","DOI":"10.1212\/WNL.0000000000009530","volume":"94","author":"SS Chung","year":"2020","unstructured":"Chung SS, French JA, Kowalski J, Krauss GL, Lee SK, Maciejowski M, et al. Randomized phase 2 study of adjunctive cenobamate in patients with uncontrolled focal seizures. Neurology. 2020;94:e2311\u201322.","journal-title":"Neurology"},{"key":"819_CR6","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/S1474-4422(19)30399-0","volume":"19","author":"GL Krauss","year":"2020","unstructured":"Krauss GL, Klein P, Brandt C, Lee SK, Milanov I, Milovanovic M, et al. Safety and efficacy of adjunctive cenobamate (YKP3089) in patients with uncontrolled focal seizures: a multicentre, double-blind, randomised, placebo-controlled, dose-response trial. Lancet Neurol. 2020;19:38\u201348.","journal-title":"Lancet Neurol"},{"key":"819_CR7","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1007\/s40263-020-00759-9","volume":"34","author":"S Lattanzi","year":"2020","unstructured":"Lattanzi S, Trinka E, Zaccara G, Striano P, Del Giovane C, Silvestrini M, et al. Adjunctive cenobamate for focal-onset seizures in adults: a systematic review and meta-analysis. CNS Drugs. 2020;34:1105\u201320.","journal-title":"CNS Drugs"},{"key":"819_CR8","doi-asserted-by":"publisher","first-page":"2329","DOI":"10.1111\/epi.16718","volume":"61","author":"M Guignet","year":"2020","unstructured":"Guignet M, Campbell A, White HS. Cenobamate (XCOPRI): Can preclinical and clinical evidence provide insight into its mechanism of action? Epilepsia. 2020;61:2329\u201339.","journal-title":"Epilepsia"},{"key":"819_CR9","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.eplepsyres.2010.09.001","volume":"92","author":"M Bialer","year":"2010","unstructured":"Bialer M, Johannessen SI, Levy RH, Perucca E, Tomson T, White HS. Progress report on new antiepileptic drugs: a summary of the Tenth Eilat Conference (EILAT X). Epilepsy Res. 2010;92:89\u2013124.","journal-title":"Epilepsy Res"},{"key":"819_CR10","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/j.ejphar.2019.05.007","volume":"855","author":"M Nakamura","year":"2019","unstructured":"Nakamura M, Cho JH, Shin H, Jang IS. Effects of cenobamate (YKP3089), a newly developed anti-epileptic drug, on voltage-gated sodium channels in rat hippocampal CA3 neurons. Eur J Pharmacol. 2019;855:175\u201382.","journal-title":"Eur J Pharmacol"},{"key":"819_CR11","doi-asserted-by":"publisher","first-page":"173117","DOI":"10.1016\/j.ejphar.2020.173117","volume":"879","author":"R Sharma","year":"2020","unstructured":"Sharma R, Nakamura M, Neupane C, Jeon BH, Shin H, Melnick SM, et al. Positive allosteric modulation of GABAA receptors by a novel antiepileptic drug cenobamate. Eur J Pharmacol. 2020;879:173117.","journal-title":"Eur J Pharmacol"},{"key":"819_CR12","doi-asserted-by":"publisher","first-page":"107966","DOI":"10.1016\/j.neuropharm.2020.107966","volume":"168","author":"GJ Sills","year":"2020","unstructured":"Sills GJ, Rogawski MA. Mechanisms of action of currently used antiseizure drugs. Neuropharmacology. 2020;168:107966.","journal-title":"Neuropharmacology"},{"key":"819_CR13","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1111\/j.1535-7597.2004.42010.x","volume":"4","author":"AL George","year":"2004","unstructured":"George AL. Inherited channelopathies associated with epilepsy. Epilepsy Curr. 2004;4:65\u201370.","journal-title":"Epilepsy Curr"},{"key":"819_CR14","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1111\/epi.12657","volume":"55","author":"LL Anderson","year":"2014","unstructured":"Anderson LL, Thompson CH, Hawkins NA, Nath RD, Petersohn AA, Rajamani S, et al. Antiepileptic activity of preferential inhibitors of persistent sodium current. Epilepsia. 2014;55:1274\u201383.","journal-title":"Epilepsia"},{"key":"819_CR15","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1124\/mol.107.039867","volume":"73","author":"AC Errington","year":"2008","unstructured":"Errington AC, St\u00f6hr T, Heers C, Lees G. The investigational anticonvulsant lacosamide selectively enhances slow inactivation of voltage-gated sodium channels. Mol Pharmacol. 2008;73:157\u201369.","journal-title":"Mol Pharmacol."},{"key":"819_CR16","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1016\/j.seizure.2013.04.015","volume":"22","author":"LJ Greenfield","year":"2013","unstructured":"Greenfield LJ. Molecular mechanisms of antiseizure drug activity at GABAA receptors. Seizure. 2013;22:589\u2013600.","journal-title":"Seizure"},{"key":"819_CR17","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1016\/j.tips.2016.04.003","volume":"37","author":"DS Reddy","year":"2016","unstructured":"Reddy DS, Estes WA. Clinical potential of neurosteroids for CNS disorders. Trends Pharmacol Sci. 2016;37:543\u201361.","journal-title":"Trends Pharmacol Sci"},{"key":"819_CR18","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.neuropharm.2017.04.020","volume":"121","author":"M L\u00e9vesque","year":"2017","unstructured":"L\u00e9vesque M, Herrington R, Leclerc L, Rogawski MA, Avoli M. Allopregnanolone decreases interictal spiking and fast ripples in an animal model of mesial temporal lobe epilepsy. Neuropharmacology. 2017;121:12\u20139.","journal-title":"Neuropharmacology"},{"key":"819_CR19","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1111\/epi.12289","volume":"54","author":"MA Rogawski","year":"2013","unstructured":"Rogawski MA, Loya CM, Reddy K, Zolkowska D, Lossin C. Neuroactive steroids for the treatment of status epilepticus. Epilepsia. 2013;54:93\u20138.","journal-title":"Epilepsia"},{"key":"819_CR20","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1002\/ana.24295","volume":"76","author":"E Broomall","year":"2014","unstructured":"Broomall E, Natale JAE, Grimason M, Goldstein J, Smith CM, Chang C, et al. Pediatric super-refractory status epilepticus treated with allopregnanolone. Ann Neurol. 2014;76:911\u20135.","journal-title":"Ann Neurol."},{"key":"819_CR21","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1002\/acn3.408","volume":"4","author":"H Vaitkevicius","year":"2017","unstructured":"Vaitkevicius H, Husain AM, Rosenthal ES, Rosand J, Bobb W, Reddy K, et al. First-in-man allopregnanolone use in super-refractory status epilepticus. Ann Clin Transl Neurol. 2017;4:411\u20134.","journal-title":"Ann Clin Transl Neurol."},{"issue":"Pt A","key":"819_CR22","doi-asserted-by":"publisher","first-page":"106939","DOI":"10.1016\/j.yebeh.2020.106939","volume":"104","author":"A Verrotti","year":"2020","unstructured":"Verrotti A, Lattanzi S, Brigo F, Zaccara G. Pharmacodynamic interactions of antiepileptic drugs: From bench to clinical practice. Epilepsy Behav. 2020;104(Pt A):106939.","journal-title":"Epilepsy Behav"},{"key":"819_CR23","unstructured":"Drug Approval Package: XCOPRI. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2019\/212839Orig1s000TOC.cfm."},{"key":"819_CR24","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1002\/cpdd.769","volume":"9","author":"L Vernillet","year":"2020","unstructured":"Vernillet L, Greene SA, Kamin M. Pharmacokinetics of cenobamate: results from single and multiple oral ascending-dose studies in healthy subjects. Clin Pharmacol Drug Dev. 2020;9:428\u201343.","journal-title":"Clin Pharmacol Drug Dev."},{"key":"819_CR25","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1007\/s13318-020-00615-7","volume":"45","author":"L Vernillet","year":"2020","unstructured":"Vernillet L, Greene SA, Kim HW, Melnick SM, Glenn K. Mass balance, metabolism, and excretion of cenobamate, a new antiepileptic drug, after a single oral administration in healthy male subjects. Eur J Drug Metab Pharmacokinet. 2020;45:513\u201322.","journal-title":"Eur J Drug Metab Pharmacokinet."},{"key":"819_CR26","doi-asserted-by":"crossref","first-page":"P1.5-034","DOI":"10.1212\/WNL.92.15_supplement.P1.5-034","volume":"92","author":"S Greene","year":"2019","unstructured":"Greene S, Orlinski L, Streicher C, Vernillet L. The pharmacokinetics of cenobamate in special populations (P1.5\u2013034). Neurology. 2019;92:P1.5-034.","journal-title":"Neurology"},{"key":"819_CR27","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1684\/epd.2014.0714","volume":"16","author":"G Zaccara","year":"2014","unstructured":"Zaccara G, Perucca E. Interactions between antiepileptic drugs, and between antiepileptic drugs and other drugs. Epileptic Disord. 2014;16:409\u201331.","journal-title":"Epileptic Disord."},{"key":"819_CR28","first-page":"S91","volume":"103","author":"L Vernillet","year":"2018","unstructured":"Vernillet L, Kamin M. Drug\u2013drug interactions between cenobamate and other antiepileptic drugs: results from phase I studies with carbamazepine, phenobarbital, phenytoin, and divalproex sodium. Clin Pharmacol Ther. 2018;103:S91.","journal-title":"Clin Pharmacol Ther."},{"key":"819_CR29","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1111\/epi.16525","volume":"61","author":"MR Sperling","year":"2020","unstructured":"Sperling MR, Klein P, Aboumatar S, Gelfand M, Halford JJ, Krauss GL, et al. Cenobamate (YKP3089) as adjunctive treatment for uncontrolled focal seizures in a large, phase 3, multicenter, open-label safety study. Epilepsia. 2020;61:1099\u2013108.","journal-title":"Epilepsia"},{"key":"819_CR30","doi-asserted-by":"crossref","unstructured":"American Society for Clinical Pharmacology and Therapeutics [abstracts]. Clin Pharmacol Ther. 2019;105:S5\u2013121.","DOI":"10.1002\/cpt.1344"},{"key":"819_CR31","unstructured":"Ewp C. Guideline on the investigation of drug interactions. 2010;44:1\u201338. https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-investigation-drug-interactions-revision-1_en.pdf."},{"key":"819_CR32","unstructured":"SK Life Science, Inc. Assess the influence of cenobamate on the PK of cytochrome P450 (CYP) Probe drugs as a means of predicting drug\u2013drug Interactions. ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/ct2\/show\/results\/NCT03234699."},{"issue":"3","key":"819_CR33","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1177\/1060028020941113","volume":"55","author":"CT Buckley","year":"2021","unstructured":"Buckley CT, Waters OR, DeMaagd G. Cenobamate: a new adjunctive agent for drug-resistant focal onset epilepsy. Ann Pharmacother. 2021;55(3):318\u201329.","journal-title":"Ann Pharmacother."},{"key":"819_CR34","unstructured":"US FDA. Cenobamate: highlights of prescribing information. Silver Spring, MD: US FDA."}],"container-title":["CNS Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-021-00819-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40263-021-00819-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-021-00819-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,30]],"date-time":"2024-08-30T23:04:53Z","timestamp":1725059093000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40263-021-00819-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,16]]},"references-count":34,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,6]]}},"alternative-id":["819"],"URL":"https:\/\/doi.org\/10.1007\/s40263-021-00819-8","relation":{},"ISSN":["1172-7047","1179-1934"],"issn-type":[{"value":"1172-7047","type":"print"},{"value":"1179-1934","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,16]]},"assertion":[{"value":"20 April 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 May 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This manuscript was not funded.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Emilio Russo has received speaker fees or funding from, and has participated in advisory boards for, Arvelle Therapeutics, Eisai, Pfizer, GW Pharmaceuticals, UCB and Lundbeck. Gaetano Zaccara has received speaker\u2019s or consultancy fees from Eisai, UCB Pharma and Jazz Pharmaceuticals, and has served on the advisory board for GW Pharmaceuticals. Simona Lattanzi has received speaker\u2019s or consultancy fees from Eisai, UCB Pharma, and GW Pharmaceuticals, and has served on advisory boards for GW Pharmaceuticals and Arvelle Therapeutics. Roberta Roberti, Carmen De Caro, Luigi F. Iannone have no conflicts of interest to declare.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Data sharing is not applicable to this manuscript as no datasets were generated or analyzed.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material (data transparency)"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"All authors participated equally in the conceptualization of the manuscript and in the writing up of the manuscript, from the initial draft to the final version. All authors have read and approved the final version.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}